Back to search

Article

Facilitating clinical trials in Polycythemia vera (PV) by identifying patient cohorts at high near-term risk of thrombosis using rich data and machine learning

2024-01-22

Abstract excerpt

Thrombosis remains the leading cause of morbidity and mortality for patients (pts) with polycythemia vera (PV), yet PV clinical trials are not powered to identify interventions that improve thrombosis-free survival (TFS). Such trials are infeasible in a contemporary PV cohort, even when selecting “high-risk” pts based on Age >60 and thrombosis history, because thousands of patients would be required for a short-te...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d4c6afc5-0164-5e3d-bc98-10b363530435
DOI
10.1101/2024.01.21.24301561
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Facilitating clinical trials in Polycythemia vera (PV) by identifying patient cohorts at high near-term risk of thrombosis using rich data and machine learningDOI 10.1101/2024.01.21.24301561
Development and validation of a multiple factor-based prognostic score system of thrombosis in polycythemia vera (MFPS-PV)Semantic proximity
Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.Semantic proximity
[Analysis of risk factors for venous thromboembolism in patients with polycythemia vera and establishment of a prediction model].Semantic proximity
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.Semantic proximity
Impact of ELN clinical signs and symptoms on the thrombotic risk in Polycythemia Vera patients treated with front-line hydroxyureaSemantic proximity
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity
European LeukemiaNet Clinical Signs and Symptoms as Prognostic Markers in Polycythemia Vera During RuxolitinibSemantic proximity
It is time to change thrombosis risk assessment for PV and ET?Semantic proximity
Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.Semantic proximity
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patientsSemantic proximity
Essential thrombocythemia treatment algorithm 2018.Semantic proximity
DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational studySemantic proximity
Select a neighboring publication to make it the new centre.